The impact of the glucagon-like peptide-1 receptor agonist liraglutide on natriuretic peptides in heart failure patients with reduced ejection fraction with and without type 2 diabetes
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
The impact of the glucagon-like peptide-1 receptor agonist liraglutide on natriuretic peptides in heart failure patients with reduced ejection fraction with and without type 2 diabetes. / Nielsen, Roni; Jorsal, Anders; Tougaard, Rasmus S.; Rasmussen, Jon J.; Schou, Morten; Videbæk, Lars; Gustafsson, Ida; Faber, Jens; Flyvbjerg, Allan; Wiggers, Henrik; Tarnow, Lise; Kistorp, Caroline.
I: Diabetes, Obesity and Metabolism, Bind 22, Nr. 11, 2020, s. 2141-2150.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - The impact of the glucagon-like peptide-1 receptor agonist liraglutide on natriuretic peptides in heart failure patients with reduced ejection fraction with and without type 2 diabetes
AU - Nielsen, Roni
AU - Jorsal, Anders
AU - Tougaard, Rasmus S.
AU - Rasmussen, Jon J.
AU - Schou, Morten
AU - Videbæk, Lars
AU - Gustafsson, Ida
AU - Faber, Jens
AU - Flyvbjerg, Allan
AU - Wiggers, Henrik
AU - Tarnow, Lise
AU - Kistorp, Caroline
N1 - Publisher Copyright: © 2020 John Wiley & Sons Ltd
PY - 2020
Y1 - 2020
N2 - Aim: To assess the effect of liraglutide, a glucagon-like peptide-1 receptor agonist, on urinary sodium excretion as well as on circulating adrenomedullin and copeptin levels in patients with type 2 diabetes (T2D). Materials and methods: In the LIVE study, patients (n = 241) with left ventricular ejection fraction ≤45% were randomized to liraglutide 1.8 mg daily or placebo for 24 weeks, and 30% had a concomitant diagnosis of T2D. Plasma levels of N-terminal brain-natriuretic-peptide (NT-proBNP) (a predefined secondary endpoint), midregional pro-atrial-natriuretic-peptide (MR-proANP), midregional pro-adrenomedullin (MR-proADM) and copeptin were measured at baseline and after 24 weeks in this substudy. The potential effect modification of T2D was assessed. Results: In the eligible subgroup of 231 patients with available biomarkers (115 randomized to liraglutide and 116 to placebo), MR-proANP decreased by 12% (P =.002) and NT-proBNP by 9% (P =.009) during liraglutide treatment compared with placebo at week 24. Interaction with T2D for the treatment effect of change in MR-proANP and NT-proBNP levels was P =.003 and P =.03, respectively. Consequently, in patients with T2D, liraglutide decreased MR-proANP by 27% (P <.001) and NT-proBNP by 25% (P =.02) compared with placebo, whereas no change was observed in patients without T2D. There was no effect of liraglutide on MR-proADM (P =.10) or copeptin (P =.52). Conclusion: Liraglutide decreased the A- and B-type natriuretic peptides significantly in patients with heart failure with reduced ejection fraction (HFrEF) and concomitant T2D, suggesting a beneficial mechanism of liraglutide in T2D patients with HFrEF.
AB - Aim: To assess the effect of liraglutide, a glucagon-like peptide-1 receptor agonist, on urinary sodium excretion as well as on circulating adrenomedullin and copeptin levels in patients with type 2 diabetes (T2D). Materials and methods: In the LIVE study, patients (n = 241) with left ventricular ejection fraction ≤45% were randomized to liraglutide 1.8 mg daily or placebo for 24 weeks, and 30% had a concomitant diagnosis of T2D. Plasma levels of N-terminal brain-natriuretic-peptide (NT-proBNP) (a predefined secondary endpoint), midregional pro-atrial-natriuretic-peptide (MR-proANP), midregional pro-adrenomedullin (MR-proADM) and copeptin were measured at baseline and after 24 weeks in this substudy. The potential effect modification of T2D was assessed. Results: In the eligible subgroup of 231 patients with available biomarkers (115 randomized to liraglutide and 116 to placebo), MR-proANP decreased by 12% (P =.002) and NT-proBNP by 9% (P =.009) during liraglutide treatment compared with placebo at week 24. Interaction with T2D for the treatment effect of change in MR-proANP and NT-proBNP levels was P =.003 and P =.03, respectively. Consequently, in patients with T2D, liraglutide decreased MR-proANP by 27% (P <.001) and NT-proBNP by 25% (P =.02) compared with placebo, whereas no change was observed in patients without T2D. There was no effect of liraglutide on MR-proADM (P =.10) or copeptin (P =.52). Conclusion: Liraglutide decreased the A- and B-type natriuretic peptides significantly in patients with heart failure with reduced ejection fraction (HFrEF) and concomitant T2D, suggesting a beneficial mechanism of liraglutide in T2D patients with HFrEF.
KW - GLP-1 analogue
KW - heart failure
KW - type 2 diabetes
U2 - 10.1111/dom.14135
DO - 10.1111/dom.14135
M3 - Journal article
C2 - 32627271
AN - SCOPUS:85089312606
VL - 22
SP - 2141
EP - 2150
JO - Diabetes, Obesity and Metabolism
JF - Diabetes, Obesity and Metabolism
SN - 1462-8902
IS - 11
ER -
ID: 263022410